June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Choroidal thickness in retinal vein occlusion: A pilot study
Author Affiliations & Notes
  • Christiana Dinah
    Ophthalmology, Royal Victoria Infirmary, Newcastle, United Kingdom
  • Dawn Sim
    Moorfields Eye Hospital, London, United Kingdom
  • Pearse Keane
    Moorfields Eye Hospital, London, United Kingdom
  • Adnan Tufail
    Moorfields Eye Hospital, London, United Kingdom
  • James Talks
    Ophthalmology, Royal Victoria Infirmary, Newcastle, United Kingdom
  • Footnotes
    Commercial Relationships Christiana Dinah, None; Dawn Sim, None; Pearse Keane, None; Adnan Tufail, Allergan (C), Bayer (C), GSK (C), Oculogics (C), Pfizer (C), Thrombogenics (C), Amakem (C), Heidelberg Engineering (R), Novarits/Alcon (C), Sanofi/Genzyme (C); James Talks, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2823. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christiana Dinah, Dawn Sim, Pearse Keane, Adnan Tufail, James Talks; Choroidal thickness in retinal vein occlusion: A pilot study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2823.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Choroidal blood flow accounts for most of the ocular blood flow and is the major source of oxygen and nutrients for the choroid and the outer retina. The choroid has also been implicated in the pathophysiology of macular oedema and retinal hypoxia. We set out to investigate the role of the choroid in retinal vein occlusion using enhanced depth optical coherence imaging (EDI-OCT). Our aim was to compare the subfoveal choroidal thickness in eyes with retinal vein occlusion with normal fellow eyes and describe changes in choroidal thickness after treatment with dexamethasone intravitreal implant (DEX implant, Allergan)

Methods: In this pilot, longitudinal study, consecutive patients with macular oedema secondary to retinal vein occlusion were evaluated. Slit lamp biomicroscopy, spectral domain optical coherence tomography and EDI-OCT were performed at baseline in the affected and the normal fellow eye. Wide-field fluorescein angiography was also performed in all patients. 10 weeks after treatment with intravitreal dexamethasone implant, EDI-OCT was repeated in the affected eyes.

Results: There were 10 eyes of 5 patients. 2 patients presented with branch retinal vein occlusion, 2 with hemi-vein occlusion and 1 patient with central retinal vein occlusion. Mean age was 69.8 (±13.4, range: 58-90), mean duration of symptoms at baseline was 18.8 weeks (±21.3, range: 3-52), mean axial length was 22.68 (±0.7, range:22.2-24.05) and mean best corrected visual acuity in early treatment of diabetes retinopathy study (ETDRS) letters was 48.2 (±24.6, range:17-73). In all 5 patients, the subfoveal choroidal thickness was thinner in the fellow eye compared to the normal eye (297.2µm vs 208.9µm). Additionally, 10 weeks after treatment with intravitreal DEX implant, choroidal thickness was lower compared to baseline in 3 of 5 affected eyes.

Conclusions: EDI-OCT provides a non-invasive method of evaluating the changes in the choroid in retinal vein occlusion. Choroidal thickness was thinner in unaffected fellow eyes, compared to eyes with retinal vein occlusion. This may indicate an increase in choroidal perfusion resulting from local mechanisms compensating for the decrease in retinal blood flow. Further work is required to elucidate the role of choroidal perfusion in visual acuity and response to treatment in retinal vein occlusion

Keywords: 749 vascular occlusion/vascular occlusive disease • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 452 choroid  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.